AZT as a telomerase inhibitor

Frontiers in Oncology

Volumn 2 SEP, Issue , 2012, Pages

  Gomez, Daniel E ^a   Armando, Romina G ^a   Alonso, Daniel F ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

AZT; Inhibitors; Telomerase; Telomere

Indexed keywords

CASPASE 3; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PACLITAXEL; PROLINE RICH PROTEIN; PROTEIN P21; TELOMERASE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IC 50; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTATIC COLORECTAL CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SENESCENCE; SHORT SURVEY; SOLID TUMOR; TELOMERE SHORTENING;

EID: 84874835783     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00113     Document Type: Short Survey

References (38)

1. Allsoop, R. C., and Harley, C. B. (1995). Evidence for a critical telomeric length in senescent human fibroblasts. Exp. Cell. Res. 219, 130-136.
2. Beltz, L., Moran, R., Elsawy, O., Sadler, J., and Jurgenson, J. (1999). The effects of telomerase inhibitors on lymphocyte function. Anticancer Res. 19, 3205-3211.
3. Bodnar, A. G., Kim, N. W., Effros, R. B., and Chiu, C. P. (1996). Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228, 58-64.
4. Brown, T., Sigurdson, E., Rogatko, A., and Broccoli, D. (2003). Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann. Surg. Oncol. 10, 910-915.
5. Campisi, J. (1997). The biology of replicative senescence. Eur. J. Cancer 33, 703-709.
6. Chang, E., and Harley, C. B. (1995). Telomere length and replicative aging in human vascular tissues. Proc. Natl. Acad. Sci. U.S.A. 92, 11190-11194.
7. Clark, J., Sikov, W., Cummings, F., Browne, M., Akerley, W., Wanebo, H., Weitberg, A., Kennedy, T., Cole, B., Bigley, J., Beitz, J., and Darnowski, J. (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J. Cancer Res. Clin. Oncol. 122, 554-558.
8. Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T. A., Hermine, O., and Nicot, C. (2006). Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108, 1021-1029.
9. Dhaeene, K., Van Marck, E., and Parwaresch, R. (2000). Telomeres, telomerase and cancer: an up-date. Virchows Arch. 437, 1-16.
10. Falchetti, A., Franchi, A., Bordi, C., Mavilia, C., Masi, L., Cioppi, F., Recenti, R., Picariello, L., Marini, F., Del Monte, F., Ghinoi, V., Martineti, V., Tanini, A., and Brandi, M. L. J. (2005). Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. Bone Miner. Res. 20, 410-418.
11. Falcone, A., Lencioni, M., Brunetti, I., Pfanner, E., Allegrini, G., Antonuzzo, A., Andreuccetti, M., Malvaldi, G., Danesi, R., Del Tacca, M., and Conte, P. F. (1997). Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann. Oncol. 8, 539-545.
12. Fang, J. L., and Beland, F. A. (2009). Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol. Sci. 111, 120-130.
13. Faraj, A., El Alaoui, A. M., Gosselin, G., Imbach, J. L., Morrow, C., and Sommadossi, J. P. (2000). Effects of beta-L-3'-azido-3'-deoxythymidine 5'-triphosphate on host and viral DNA polymerases. Antiviral Res. 47, 97-102.
14. Gan, Y., Mo, Y., Johnston, J., Lu, J., Wientjes, M. G., and Au, J. L. (2002). Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett. 527, 10-14.
15. Gomez, D., Kassim, A., and Olivero, O. (1995). Preferential incorporation of 3'-azido-2',3'-dideoxythymidine (AZT) in telomeric sequences of cho cells. Int. J. Oncol. 7, 1057-1060.
16. Gomez, D. E., Tejera, A. M., and Olivero, O. A. (1998). Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment. Biochem. Biophys. Res. Commun. 246, 107-110.
17. Haïk, S., Gauthier, L. R., Granotier, C., Peyrin, J. M., Lages, C. S., Dormont, D., and Boussin, F. D. (2000). Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells. Oncogene 19, 2957-2966.
18. Hájec, M., Matulová, N., Votruba, I., Holỳ, A., and Tloust'ová, E. (2005). Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem. Pharmacol. 15, 894-900.
19. Harley, C. B., Futcher, A. B., and Greider, C. W. (1991). Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460.
20. Jeng, K. S., Sheen, I. S., and Jeng, W. J. (2011). Azidothymidine treatment of hepatocellular carcinoma in rats: an in vivo study of telomerase inhibition. Hepatogastroenterology 58, 2091-2096.
21. Ji, H. J., Rha, S. Y., Jeung, H. C., Yang, S. H., An, S. W., and Chung, H. C. (2005). Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res. Treat. 93, 227-236.
22. Johnston, J. S., Johnson, A., Gan, Y., Wientjes, M. G., and Au, J. L. (2003). Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm. Res. 20, 957-961.
23. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
24. Lavelle, F., Riou, J. F., Laoui, A., and Mailliet, P. (2000). Telomerase: a therapeutic target for the third millennium? Crit. Rev. Oncol. Hematol. 34, 111-126.
25. Marchbanks, K., Dudley, M. N., Posner, M. R., and Darnowski, J. (1995). Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Pharmacotherapy 15, 451-457.
26. Melana, S. M., Holland, J. F., and Pogo, B. G. (1998). Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-Azido-3'-deoxythymidine. Clin. Cancer Res. 4, 693-696.
27. Miller, K. D., Loehrer, P. J., Gonin, R., Weber, G., Ansari, R., Pletcher, W., McClean, J., Spiridonidis, C. H., and Mortimer, J. (1996). A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. Invest. New Drugs 14, 207-212.
28. Morgan, R. J. Jr., Newman, E. M., Sowers, L., Scanlon, K., Harrison, J., Akman, S., Leong, L., Margolin, K., Niland, J., Raschko, J., Somlo, G., Carroll, M., Chow, W., Tetef, M., Hamasaki, V., Yen, Y., and Doroshow, J. H. (2003). Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother. Pharmacol. 51, 459-464.
29. Multani, A. S., Furlong, C., and Pathak, S. (1998). Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3'-azido-2'-3'-dideoxythymidine. Int. J. Oncol. 13, 923-925.
30. Murakami, J., Nagai, N., Shigemasa, K., and Ohama, K. (1999). Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur. J. Cancer 35, 1027-1034.
31. Olivero, O. A., Anderson, L. M., Diwan, B. A., Haines, D. C., Harbaugh, S. W., Moskal, T. J., Jones, A. B., Rice, J. M., Riggs, C. W., Logsdon, D., Yuspa, S. H., and Poirier, M. C. (1997). Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 5, 1602-1608.
32. Olivero, O. A., and Poirier, M. C. (1993). Preferential incorporation of 3'-azido-2',3'-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells. Mol. Carcinog. 8, 81-88.
33. Posner, M. R., Darnowski, J. W., Weitberg, A. B., Dudley, M. N., Corvese, D., Cummings, F. J., Clark, J., Murray, C., Clendennin, N., Bigley, J., and Culabresi, P. (1992). High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 15, 2929-2934.
34. Strahl, C., and Blackburn, E. H. (1994). The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res. 25, 893-900.
35. Strahl, C., and Blackburn, E. H. (1996). Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16, 53-65.
36. Tejera, A. M., Alonso, D. F., Gomez, D. E., and Olivero, O. A. (2001). Chronic in vitro exposure to 3'-azido-2', 3'-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells. Breast Cancer Res. Treat. 65, 93-99.
37. Vaziri, H., and Benchimol, S. (1998). Reconstitution of telomerase activity in normal human cells lead to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279-282.
38. Yegorov, Y. E., Chernov, D. N., Akimov, S. S., Bolsheva, N. L., Krayevsky, A. A., and Zelenin, A. V. (1996). Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett. 1, 115-118.